Prenetics (NASDAQ: PRE) raises 2026 revenue guidance and signs Diplo as a shareholder

What happened

Prenetics Global Limited (NASDAQ: PRE) signed Diplo as an IM8 Global Ambassador and a Prenetics shareholder and raised 2026 revenue guidance to $220 million to $230 million.

The Nov. 16 release says the multi-year global partnership makes the three-time GRAMMY winner IM8's first ambassador from music. Prenetics also set 2027 IM8 revenue guidance of $400 million or more, which assumes no revenue from upcoming product launches.

For holders, the guidance matters more than the signing. It sets a 2027 target for IM8 without counting those launches.

Key numbers

Metric Latest Change Source
Full-year 2026 revenue guidance $220 million to $230 million Prenetics press release, Exhibit 99.1 to SEC 6-K
2027 IM8 revenue guidance $400 million or more Prenetics press release, Exhibit 99.1 to SEC 6-K
IM8 revenue, second quarter of 2026 $45 million +359% (approximately, year over year) Prenetics press release, Exhibit 99.1 to SEC 6-K
IM8 monthly revenue, July 2026 $20.9 million Prenetics press release, Exhibit 99.1 to SEC 6-K
IM8 annualized revenue run-rate, July 2026 approximately $251 million Prenetics press release, Exhibit 99.1 to SEC 6-K

Read more: Prenetics Global (PRE) company research

What Diplo brings to IM8

Diplo has more than 12 million followers across Instagram, TikTok and YouTube and more than 40 million monthly listeners on Spotify, the release says. IM8 becomes his exclusive partner in the all-in-one nutrition and longevity categories.

He joins David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, Lily Collins and Inter Miami CF on what the release calls an equity-aligned roster. CEO Danny Yeung said Diplo, like every ambassador before him, is a shareholder, not a spokesperson.

IM8 joined Diplo's Run Club in New York on Oct. 24 and in Los Angeles on Nov. 8. It will be on site in San Diego on Nov. 21 and in Phoenix on Jan. 23, 2027.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

The IM8 numbers behind the guidance

The new targets rest on a brand that is still growing fast. In the second quarter of 2026, IM8 generated $45 million in revenue, up approximately 359% year over year. It was the sixth record quarter in a row.

In July, IM8 recorded $20.9 million in monthly revenue, an annualized run-rate of approximately $251 million 20 months after launch. Within 12 months of launch the run-rate was $120 million, so it kept climbing well after the first year.

Why it matters

The guidance supports the revenue-growth side of the Prenetics story. Both the raised 2026 range and the first 2027 IM8 target are company estimates, not reported results.

The two guidance figures cover different scopes. The 2026 range is for Prenetics revenue. The 2027 target is for IM8 alone. They should not be set against each other directly.

The run-rate has limits, the release says. It annualizes a single month and assumes that month's revenue holds for the next twelve. It is sensitive to promotions, product launches and billing cycles, because quarterly subscription plans are recognized in full when the three-month supply ships.

What's next

IM8 Hydration is slated to launch in Q1 of 2027, and Care Bears by IM8 in the first half of 2027. Any revenue they bring falls outside the assumptions behind the 2027 guidance.

IM8 revenue holding near July's level without help from those launches would strengthen the case. A monthly figure that slips back would leave the 2027 target resting on the launches the guidance excludes.

More from OptimistFi

From OptimistFi Perps

Sources

Explore OptimistFi research on Prenetics Global Limited: https://optimistfi.com/stocks/PRE

Browse Prenetics Global Limited company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the Prenetics Global Limited company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.